Friday, July 10, 2026
🇺🇸 FDA

pharma · Muscle-invasive bladder cancer (MIBC) · Acute ischaemic stroke due to basilar artery occlusion.

Tour Hekla

Tour Hekla trial registry — 27 ClinicalTrials.gov studies with program phase, status, and indication context.

Website Investor relations
Puteaux, Ile de France 92800, FR HQ
6 Employees
EMA registrant Type
Company details
Status
Public
HQ
Puteaux, Ile de France 92800, FR
Employees
6
Programs
27
Drugs
71
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Trials

Tour Hekla clinical trials

Registry index of 27 ClinicalTrials.gov studies linked to Tour Hekla programs — each row shows trial ID, program name, phase, status, and indication.

Tour Hekla trial registry — 27 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for Tour Hekla.

  1. DR240305 — Approved

    Clinical update

  2. DR230070 — Phase 2

    Clinical update

  3. OPDIVO for Unresectable locally advanced o… — Phase 2

    Clinical update

  4. DR220204 — Phase 2

    Clinical update

  5. KALINOX 50%/50% for Treatment of suicidal ideation — Phase 2

    Clinical update

  6. TOUR006-T01 — Phase 2

    Clinical update

  7. SOGUG2020IEC(VEJ)11 — Phase 2

    Clinical update

  8. RIPH_2019_01 — Phase 3

    Clinical update

Trial registry

27 studies
  12. 2024-511985-34-00

    DR230314

    Approved active small_molecule

    Evaluation of the CKD-Epi score to identify a glomerular filtration threshold predictive of morphine failure at usual dosage, using a reference method for assessing renal function: iohexol clearance. All other aspects of the protocol are part of standard care practice.

    CTIS ↗
  21. 2024-515955-39-01

    Rapamune 1 mg/mL oral solution

    Phase 2 active small_molecule

    Lingual microcystic lymphatic malformations (LMLMs) are rare congenital vascular malformations, presenting as clusters of cysts filled with lymph fluid or blood. They are responsible for a heavy burden even with small well-limited lesions because of oozing, bleeding, infections, or even speech, chewing or breathing impairment. Pain and aesthetic prejudice are also frequently reported

    CTIS ↗
  25. 2024-519461-22-00

    DR240305

    Approved active small_molecule

    Attention Deficit Disorder with or without Hyperactivity (ADHD) is a neurodevelopmental disorder characterized by disabling symptoms of inattention and/or hyperactivity-impulsivity beginning before the age of 12 with significant personal, social, academic and/or occupational impact (American Psychiatric Association 2013). This disorder, whose prevalence is around 5% in children and adolescents, affects 2.6% of adults (American Psychiatric Association 2013; Song et al. 2021).

    CTIS ↗
  26. 2024-519894-20-01

    RIPH_2019_01

    Phase 3 active small_molecule

    Adult with an staphylococcal prosthetic joint infection treated with debridement, antibiotics and implant retention (DAIR strategy)

    CTIS ↗

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.